Women's Health Investment Has An Evidence Problem

Women's Health Investment Has An Evidence Problem
By: Women's HealthX Editorial

47% of health plan leaders cite a lack of ROI data as the biggest barrier to broader women's health coverage.

Boston MA -- September 21: Women's health has never had more attention.

But according to contributors to the Women's Health Infrastructure Report 2026, attention alone isn't enough.

47%
of health plan leaders cite ROI data as the biggest barrier to expanding women's health coverage

47% of health plan respondents identified a lack of longitudinal ROI data as the primary operational barrier preventing broader coverage of specialized women's health solutions.

What Health Plans Say Is Holding Women's Health Back
Lack of Longitudinal ROI Data
47%
Actuarial Risk Uncertainty
29%
Employer Demand Gaps
11%
Regulatory Integration
12%

By comparison, actuarial risk uncertainty accounted for 29% of responses, while employer demand gaps and regulatory integration received 11% and 12% respectively.

What This Means
Women's health investment is no longer being held back by awareness. It is being held back by evidence.

Future growth in women's health coverage may depend less on generating demand and more on generating evidence.

This finding represents just one of dozens of insights uncovered through the Women's Health Infrastructure Report 2026, a cross-sector study bringing together perspectives from health plans, providers, employers, clinicians, life sciences organisations and innovators.

The full report features detailed findings, expert commentary, benchmark data and practical implications for healthcare leaders looking to understand where women's health is heading next.

Lead Research Partner
Foraviset

Women’s HealthX 2026 | From Rhetoric to Results

Encore Boston Harbor | December 3-4 2026

Bypass abstract market rhetoric to evaluate real-world health economics, regulatory compliance mandates, and care delivery systems. Join the region's foremost health plan medical directors, hospital COOs, biopharma innovators, and enterprise benefits buyers anchoring our 2026 tracks.